Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
SCYXJERSEY CITY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that a novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform are among the five projects funded by the federal grant awarded to the new accelerator consortium led by researchers from Hackensack Meridian Center for Discovery and Innovation (CDI) and the Johns Hopkins Bloomberg School of Public Health. A five-year federal grant will establish a Center of Excellence in Translational Research (CETR) jointly between researchers from the Bloomberg School and the CDI, and other academic and commercial collaborators. The CETR expects to receive about $7 million annually, contingent upon the availability of funds, with the support coming from the National Institutes of Health’s National Institute of Allergy and Infectio
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
SCYX(NASDAQ:SCYX) JERSEY CITY, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced multiple upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the upcoming 12th Congress on Trends in Medical Mycology (TIMM-12), which is scheduled to take place from September 19th to 22nd, 2025, in Bilbao, Spain.
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
SCYXJERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior leadership team will participate in the H.C. Wainwright 27th Annual Global Conference.
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
SCYXJERSEY CITY, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2025.
SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study Following Lifting Of Clinical Hold
SCYXSCYNEXIS Q1 EPS $(0.11) Beats $(0.17) Estimate, Sales $257.00K Beat $205.50K Estimate
SCYXSCYNEXIS To Present Preclinical Data On Second Generation IV/Oral Fungerp SCY-247 At The European Society Of Clinical Microbiology And Infectious Diseases
SCYXSCYNEXIS 2024 GAAP EPS $(0.44) Down From $1.39 YoY, Sales $3.75M Down From $140.14M YoY
SCYXSCYNEXIS Q3 EPS $(0.06) Beats $(0.07) Estimate
SCYXLooking Into SCYNEXIS's Return On Capital Employed
SCYXBenzinga Pro data, SCYNEXIS (NASDAQ:SCYX) reported Q2 sales of $1.32 million. Earnings fell to a loss of $13.35 million, resulting in a 144.82% decrease from last quarter.
SCYNEXIS To Present New Data Of Ibrexafungerp For Refractory Vulvovaginal Candidiasis From Ongoing Phase 3 FURI Study At The American College Of Obstetricians And Gynecologists Annual Clinical & Scientific Meeting On May 6
SCYX